PLX Protalix BioTherapeutics PE ratio, current and historical analysis
As of Apr 23, 2025, the Protalix BioTherapeutics stock's PE ratio is 74.0. This takes into account the latest EPS of $0.04 and stock price of $2.96.
PLX PE ratio history
The PE ratio of Protalix BioTherapeutics has averaged 12.41 over the last ten years. The current price-to-earnings ratio of 74.0 is in line with the historical average. Analyzing the last ten years, PLX's PE ratio reached its highest point in the Dec 2024 quarter at 47, when the price was $1.88 and the EPS was $0.04. The lowest point was recorded in the Sep 2016 quarter, when it reached 1.14 with a price of $5.7 and an EPS of $5.
Protalix BioTherapeutics PE ratio by year
Maximum annual increase: 216.93% in 2024
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2024 | 47 | 216.93% | $1.88 | $0.04 |
| 2023 | 14.83 | N/A | $1.78 | $0.12 |
| 2022 | N/A | N/A | $1.37 | -$0.31 |
| 2021 | N/A | N/A | $0.83 | -$0.62 |
| 2020 | N/A | N/A | $3.63 | -$0.22 |
| 2019 | N/A | N/A | $3.28 | -$1.23 |
| 2018 | N/A | N/A | $3.11 | -$1.8 |
| 2017 | N/A | N/A | $6.61 | -$6.37 |
| 2016 | N/A | N/A | $4.45 | -$2.9 |
| 2015 | 1.67 | N/A | $10.2 | $6.1 |
| 2014 | N/A | N/A | $18.4 | -$3.2 |
| 2013 | N/A | N/A | $38.9 | -$3 |
| 2012 | N/A | N/A | $51.9 | -$1.3 |
| 2011 | N/A | N/A | $49.3 | -$4.3 |
| 2010 | N/A | N/A | $99.8 | -$3.6 |
Protalix BioTherapeutics PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Dec 2024 | 47 | N/A | $1.88 | $0.04 |
| Sep 2024 | N/A | N/A | $1.02 | -$0.15 |
| Jun 2024 | N/A | N/A | $1.17 | -$0.22 |
| Mar 2024 | 12.6 | -15.04% | $1.26 | $0.1 |
| Dec 2023 | 14.83 | 25.04% | $1.78 | $0.12 |
| Sep 2023 | 11.86 | -40.7% | $1.66 | $0.14 |
| Jun 2023 | 20 | N/A | $2 | $0.1 |
| Mar 2023 | N/A | N/A | $2.1 | -$0.3 |
| Dec 2022 | N/A | N/A | $1.37 | -$0.31 |
| Sep 2022 | N/A | N/A | $1.04 | -$0.37 |
| Jun 2022 | N/A | N/A | $1.09 | -$0.39 |
| Mar 2022 | N/A | N/A | $1.06 | -$0.53 |
| Dec 2021 | N/A | N/A | $0.83 | -$0.62 |
| Sep 2021 | N/A | N/A | $1.33 | -$0.45 |
| Jun 2021 | N/A | N/A | $1.91 | -$0.5 |
PLX average PE ratio chart
The current PE ratio of PLX is above its 3, 5 and 10-year averages.
PLX PE vs peers
When compared to its peer stocks PFE and NBIX, PLX's PE ratio is higher.
| Stock name | PE ratio | Market cap |
|---|---|---|
| PFE Pfizer Inc | 15.71 | $126.41B |
| NBIX Neurocrine Biosciences Inc | 30.36 | $10.29B |
| PLX Protalix BioTherapeutics Inc | 76 | $237.22M |
| FOLD Amicus Therapeutics Inc | N/A | $2.11B |
| TEVA Teva Pharmaceutical Industries Ltd | N/A | $16.24B |
Frequently asked questions
What is Protalix BioTherapeutics's PE ratio?
As of Apr 23, 2025, PLX stock has a price to earnings ratio of 74.
What is the 3-year average PE ratio for Protalix BioTherapeutics (PLX)?
Over the last 3 years, the average PE ratio for PLX stock is 21.26.
What is the 5-year average PE ratio for Protalix BioTherapeutics (PLX)?
Over the last 5 years, the average PE ratio for PLX stock is 21.26.
What is the highest PE ratio for PLX?
Within the last ten years, the current price to earnings ratio is at its peak with a value of 74.
How does the current PE ratio for PLX compare to its historical average?
PLX's price to earnings ratio is currently 496% above its 10-year historical average.
Why is Protalix BioTherapeutics's PE ratio so high?
PLX's PE ratio is high because its earnings per share (EPS) is low relative to its stock price.
How is PLX's PE ratio calculated (Protalix BioTherapeutics PE ratio formula)?
You can calculate the P/E ratio by dividing the most recent stock price by the trailing twelve months earnings per share(EPS). As of today (Apr 23, 2025), Protalix BioTherapeutics's share price is $2.96. The company's earnings per share for the trailing twelve months (TTM) ending Dec 2024 is $0.04. Therefore, Protalix BioTherapeutics's price to earnings ratio for today is 74. PE RATIO(74) = STOCK PRICE($2.96) / TTM EPS($0.04)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from 
and Sharadar.